Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Freelance.com

Start price
Target price
Perf. (%)
€6.21
18.10.22
€7.00
18.10.23
-48.07%
19.10.23

Could be worthwhile Investment >10% per year
Aveo Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€14.70
18.10.22
-
18.10.23
0.78%
29.10.22

Capable Management
Probably not worthwhile Investment
Little innovation
Few uniques
buy
ShiftPixy Inc.

Start price
Target price
Perf. (%)
€12.20
18.10.22
-
18.10.23
72.13%
15.11.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
buy
CropEnergies AG

Start price
Target price
Perf. (%)
€15.04
17.10.22
€25.00
17.10.23
3.46%
29.10.22

Revenue growth >5% per year expected
Higher EBIT margin than peer group
Innovative
Sustainability is very important
buy
Adler Real Estate AG

Start price
Target price
Perf. (%)
€7.22
17.10.22
€8.00
17.10.23
-1.39%
20.03.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Sfc Energy AG

Start price
Target price
Perf. (%)
€16.70
17.10.22
€19.00
17.10.23
14.73%
18.10.23

Could be worthwhile Investment >10% per year
buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€3.84
17.10.22
-
17.10.23
40.63%
18.05.23

Risky Investment
buy
Blue Apron Holdings Inc.

Start price
Target price
Perf. (%)
€26.90
17.10.22
€54.00
17.10.23
7.36%
02.11.22

Could be very worthwhile Investment >20% year
buy
Copper Mountain Mining

Start price
Target price
Perf. (%)
€1.40
17.10.22
-
17.10.23
23.83%
18.10.23

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Future proof or reliable business model
Revenue growth >5% per year expected
buy
ITM Power plc

Start price
Target price
Perf. (%)
€1.08
17.10.22
€2.00
17.10.23
-21.91%
18.10.23

Medium risks for its business
Innovative
Sustainability is important
Significant cyclical dependencies
Mag Silver Corp.

Start price
Target price
Perf. (%)
€12.89
17.10.22
-
17.10.23
-2.21%
30.01.23

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Jaguar Mining Inc.

Start price
Target price
Perf. (%)
€2.05
17.10.22
-
17.10.23
-4.87%
23.01.23

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
buy
Tricida

Start price
Target price
Perf. (%)
€12.98
17.10.22
-
17.10.23
-95.08%
25.10.22

Risky Investment
buy
Homology Medicines Inc

Start price
Target price
Perf. (%)
€1.31
16.10.22
-
16.10.23
-17.62%
27.12.22

Risky Investment
buy
TCR2 Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.68
16.10.22
-
16.10.23
-6.83%
30.10.22

Could be very worthwhile Investment >20% year
Hypoport SE

Start price
Target price
Perf. (%)
€86.20
16.10.22
€90.00
16.10.23
-4.58%
17.10.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Standard Investments for future growth
buy
Energiekontor

Start price
Target price
Perf. (%)
€87.50
15.10.22
€95.00
15.10.23
-17.49%
16.10.23

Could be worthwhile Investment >10% per year
buy
CropEnergies AG

Start price
Target price
Perf. (%)
€14.22
15.10.22
€15.50
15.10.23
6.75%
25.10.22

Could be worthwhile Investment >10% per year
buy
Delignit AG

Start price
Target price
Perf. (%)
€5.10
15.10.22
€7.00
15.10.23
-17.25%
16.10.23

Could be worthwhile Investment >10% per year
buy
Nordex SE

Start price
Target price
Perf. (%)
€8.29
15.10.22
€9.50
15.10.23
25.63%
16.10.23

Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.

Start price
Target price
Perf. (%)
€4.54
15.10.22
€2.00
15.10.23
-0.88%
29.10.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Banca Monte dei Paschi di Siena SpA

Start price
Target price
Perf. (%)
€2.05
15.10.22
€4.00
15.10.23
-4.85%
29.10.22

EBIT decline/stagnation expected
High valuation
negative Cash Flow expected
Business model of the past or high risk
buy
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.63
14.10.22
€5.00
14.10.23
-84.59%
15.10.23

Could be worthwhile Investment >10% per year
buy
B.R.A.I.N. Biotechnology Research and Information Network AG

Start price
Target price
Perf. (%)
€4.98
13.10.22
-
13.10.23
-18.27%
14.10.23

buy
Novavax Inc.

Start price
Target price
Perf. (%)
€21.36
13.10.22
€20.00
13.10.23
-48.44%
11.01.23

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float